110. Capper MJ, Yang S, Stone AC, Vatansever S, Zilberg G, Mathiharan YK, Habib R, Hutchinson K, Zhao Y, Schlessinger A, Mezei M, Osman R, Zhang B, Wacker D. Substrate binding and inhibition of the anion exchanger 1 transporter. Nat Struct Mol Biol. 2023 Oct;30(10):1495-1504. doi: 10.1038/s41594-023-01085-6. Epub 2023 Sep 7. PMID: 37679563; PMCID: PMC11008770.
109. Stein D, Kars ME, Wu Y, Bayrak ÇS, Stenson PD, Cooper DN, Schlessinger A, Itan Y. Genome-wide prediction of pathogenic gain- and loss-of-function variants from ensemble learning of a diverse feature set. Genome Med. 2023 Nov 30;15(1):103. doi: 10.1186/s13073-023-01261-9. PMID: 38037155; PMCID: PMC10688473.
108. Duffy Á, Petrazzini BO, Stein D, Park JK, Forrest IS, Gibson K, Vy HM, Chen R, Márquez-Luna C, Mort M, Verbanck M, Schlessinger A, Itan Y, Cooper DN, Rocheleau G, Jordan DM, Do R. Development of a human genetics-guided priority score for 19,365 genes and 399 drug indications. Nat Genet. 2024 Jan;56(1):51-59. doi: 10.1038/s41588-023-01609-2. Epub 2024 Jan 3. PMID: 38172303.
107. Hutchinson K, Schlessinger A. Comprehensive Characterization of LAT1 Cholesterol-Binding Sites. J Chem Theory Comput. 2024 Apr 23;20(8):3349-3358. doi: 10.1021/acs.jctc.3c01391. Epub 2024 Apr 10. PMID: 38597304.
106. Silva DB, Trinidad M, Ljungdahl A, Revalde JL, Berguig GY, Wallace W, Patrick CS, Bomba L, Arkin M, Dong S, Estrada K, Hutchinson K, LeBowitz JH, Schlessinger A, Johannesen KM, Møller RS, Giacomini KM, Froelich S, Sanders SJ, Wuster A. Haploinsufficiency underlies the neurodevelopmental consequences of SLC6A1 variants. Am J Hum Genet. 2024 Jun 6;111(6):1222-1238. doi: 10.1016/j.ajhg.2024.04.021. Epub 2024 May 22. PMID: 38781976; PMCID: PMC11179425.
105. Herrington NB, Stein D, Li YC, Pandey G, Schlessinger A. Exploring the Druggable Conformational Space of Protein Kinases Using AI-Generated Structures. bioRxiv [Preprint]. 2023 Sep 2:2023.08.31.555779. doi: 10.1101/2023.08.31.555779. PMID: 37693436; PMCID: PMC10491245.
104. Schlessinger A, Zatorski N, Hutchinson K, Colas C. Targeting SLC transporters: small molecules as modulators and therapeutic opportunities. Trends Biochem Sci. 2023 Sep;48(9):801-814. doi: 10.1016/j.tibs.2023.05.011. Epub 2023 Jun 22. PMID: 37355450; PMCID: PMC10525040.
103. Zatorski N, Sobie EA, Schlessinger A. Mavacamten improves symptoms in obstructive hypertrophic cardiomyopathy patients. Trends Pharmacol Sci. 2023 May;44(5):318-319. doi: 10.1016/j.tips.2023.02.005. Epub 2023 Mar 12. PMID: 36914446; PMCID: PMC10288863.
102. Dong Y, Wang J, Garibsingh RA, Hutchinson K, Shi Y, Eisenberg G, Yu X, Schlessinger A, Grewer C. Conserved allosteric inhibition mechanism in SLC1 transporters. Elife. 2023 Mar 1;12:e83464. doi: 10.7554/eLife.83464. PMID: 36856089; PMCID: PMC10017108.
101. Zatorski N, Sun Y, Elmas A, Dallago C, Karl T, Stein D, Rost B, Huang KL, Walsh M, Schlessinger A. Structural Analysis of Genomic and Proteomic Signatures Reveal Dynamic Expression of Intrinsically Disordered Regions in Breast Cancer and Tissue. bioRxiv [Preprint]. 2023 Feb 24:2023.02.23.529755. doi: 10.1101/2023.02.23.529755. PMID: 36865220; PMCID: PMC9980136.
100. Hutchinson K, Silva DB, Bohlke J, Clausen C, Thomas AA, Bonomi M, Schlessinger A. Describing inhibitor specificity for the amino acid transporter LAT1 from metainference simulations. Biophys J. 2022 Dec 6;121(23):4476-4491. doi: 10.1016/j.bpj.2022.11.001. Epub 2022 Nov 11. PMID: 36369754; PMCID: PMC9748366.
99. Koleske ML, McInnes G, Brown JEH, Thomas N, Hutchinson K, Chin MY, Koehl A, Arkin MR, Schlessinger A, Gallagher RC, Song YS, Altman RB, Giacomini KM. Functional genomics of OCTN2 variants informs protein-specific variant effect predictor for Carnitine Transporter Deficiency. Proc Natl Acad Sci U S A. 2022 Nov 16;119(46):e2210247119. doi: 10.1073/pnas.2210247119. Epub 2022 Nov 7. PMID: 36343260; PMCID: PMC9674959.
98. Ndaru E, Zielewicz L, Shi Y, Hutchinson K, Garibsingh RA, Schlessinger A, Grewer C. Alanine serine cysteine transporter (ASCT) substrate binding site properties probed with hydroxyhomoserine esters. J Phys Org Chem. 2022 Nov; 35(11):e4347. doi: 10.1002/poc.4347. Epub 2022 Mar 21. PMID: 36568026; PMCID: PMC9786560.
97. Zatorski N, Stein D, Rahman R, Iyengar R, Schlessinger A. Structural signatures: a web server for exploring a database of and generating protein structural features from human cell lines and tissues. Database (Oxford). 2022 Jul 26;2022:baac053. doi: 10.1093/database/baac053. PMID: 35881481; PMCID:
PMC9319604.
96. Schlessinger A, Bonomi M. Exploring the conformational diversity of proteins. Elife. 2022 Apr 21;11:e78549. doi: 10.7554/eLife.78549. PMID: 35443909; PMCID: PMC9023052.
95. Sevim Bayrak C, Stein D, Jain A, Chaudhary K, Nadkarni GN, Van Vleck TT, Puel A, Boisson-Dupuis S, Okada S, Stenson PD, Cooper DN, Schlessinger A*, Itan Y. Identification of discriminative gene-level and protein-level features associated with pathogenic gain-of-function and loss-of-function variants. Am J Hum Genet. 2021 Dec 2;108(12):2301-2318. doi: 10.1016/j.ajhg.2021.10.007.
94. Xiong Z, Jeon M, Allaway RJ, Kang J, Park D, Lee J, Jeon H, Ko M, Jiang H, Zheng M, Tan AC, Guo X; Multi-Targeting Drug DREAM Challenge Community, Dang KK, Tropsha A, Hecht C, Das TK, Carlson HA, Abagyan R, Guinney J, Schlessinger A*, Cagan R. Crowdsourced identification of multi-target kinase inhibitors for RET- and TAU- based disease: The Multi-Targeting Drug DREAM Challenge. PLoS Comput Biol. 2021 Sep 14;17(9):e1009302. doi: 10.1371/journal.pcbi.1009302.
93. Garibsingh RA, Ndaru E, Garaeva AA, Shi Y, Zielewicz L, Zakrepine P, Bonomi M, Slotboom DJ, Paulino C, Grewer C, Schlessinger A. Rational design of ASCT2 inhibitors using an integrated experimental-computational approach. Proc Natl Acad Sci U S A. 2021 Sep 14;118(37):e2104093118. doi: 10.1073/pnas.2104093118.
92. Dvorak V, Wiedmer T, Ingles-Prieto A, Altermatt P, Batoulis H, Bärenz F, Bender E, Digles D, Dürrenberger F, Heitman LH, IJzerman AP, Kell DB, Kickinger S, Körzö D, Leippe P, Licher T, Manolova V, Rizzetto R, Sassone F, Scarabottolo L, Schlessinger A, Schneider V, Sijben HJ, Steck AL, Sundström H, Tremolada S, Wilhelm M, Wright Muelas M, Zindel D, Steppan CM, Superti-Furga G. An Overview of Cell-Based Assay Platforms for the Solute Carrier Family of Transporters. Front Pharmacol. 2021 Aug 10;12:722889. doi: 10.3389/fphar.2021.722889.
91. Bernhofer M, Dallago C, Karl T, Satagopam V, Heinzinger M, Littmann M, Olenyi T, Qiu J, Schütze K, Yachdav G, Ashkenazy H, Ben-Tal N, Bromberg Y, Goldberg T, Kajan L, O’Donoghue S, Sander C, Schafferhans A, Schlessinger A, Vriend G, Mirdita M, Gawron P, Gu W, Jarosz Y, Trefois C, Steinegger M, Schneider R, Rost B. PredictProtein – Predicting Protein Structure and Function for 29 Years. Nucleic Acids Res. 2021 Jul 2;49(W1):W535-W540.
90. Adamopoulos C, Ahmed TA, Tucker MR, Ung PMU, Xiao M, Karoulia Z, Amabile A, Wu X, Aaronson SA, Ang C, Rebecca VW, Brown BD, Schlessinger A, Herlyn M, Wang Q, Shaw DE, Poulikakos PI. Exploiting Allosteric Properties of RAF and MEKInhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling. Cancer Discov. 2021 Jul;11(7):1716-1735. doi: 10.1158/2159-8290.CD-20-1351.
89. Tang CC, Castro Andrade CD, O’Meara MJ, Yoon SH, Sato T, Brooks DJ, Bouxsein ML, Martins JDS, Wang J, Gray NS, Misof B, Roschger P, Blouin S, Klaushofer K, Velduis-Vlug A, Vegting Y, Rosen CJ, O’Connell D, Sundberg TB, Xavier RJ, Ung P, Schlessinger A, Kronenberg HM, Berdeaux R, Foretz M, Wein MN. Dual targeting of salt inducible kinases and CSF1R uncouples bone formation and bone resorption. Elife. 2021 Jun 23;10:e67772. doi: 10.7554/eLife.67772.
88. Cichońska A, Ravikumar B, Allaway RJ, Wan F, Park S, Isayev O, Li S, Mason M, Lamb A, Tanoli Z, Jeon M, Kim S, Popova M, Capuzzi S, Zeng J, Dang K, Koytiger G, Kang J, Wells CI, Willson TM; IDG-DREAM Drug-Kinase Binding Prediction Challenge Consortium, Oprea TI, Schlessinger A, Drewry DH, Stolovitzky G, Wennerberg K, Guinney J, Aittokallio T. Crowdsourced mapping of unexplored target space of kinase inhibitors. Nat Commun. 2021 Jun 3;12(1):3307. doi: 10.1038/s41467-021-23165-1.
87. Rahman R, Zatorski N, Hansen J, Xiong Y, van Hasselt JGC, Sobie EA, Birtwistle MR, Azeloglu EU, Iyengar R, Schlessinger A. Protein structure-based gene expression signatures. Proc Natl Acad Sci U S A. 2021 May 11;118(19):e2014866118. doi: 10.1073/pnas.2014866118.
86. Vatansever S, Schlessinger A, Wacker D, Kaniskan HÜ, Jin J, Zhou MM, Zhang B. Artificial intelligence and machine learning-aided drug discovery in central nervous system diseases: State-of-the-arts and future directions. Med Res Rev. 2021 May;41(3):1427-1473. doi: 10.1002/med.21764.
85. Kodesh A, Levine SZ, Khachadourian V, Rahman R, Schlessinger A, O’Reilly PF, Grove J, Schendel D, Buxbaum JD, Croen L, Reichenberg A, Sandin S, Janecka M. Maternal health around pregnancy and autism risk: a diagnosis-wide, population- based study. Psychol Med. 2021 Mar 26:1-9. doi: 10.1017/S0033291721001021.
84. Venteicher B, Merklin K, Ngo HX, Chien HC, Hutchinson K, Campbell J, Way H, Griffith J, Alvarado C, Chandra S, Hill E, Schlessinger A, Thomas AA. The Effects of Prodrug Size and a Carbonyl Linker on l-Type Amino Acid Transporter 1-Targeted Cellular and Brain Uptake. ChemMedChem. 2021 Mar 3;16(5):869-880. doi: 10.1002/cmdc.202000824.
83. Lizarraga SB, Ma L, Maguire AM, van Dyck LI, Wu Q, Ouyang Q, Kavanaugh BC, Nagda D, Livi LL, Pescosolido MF, Schmidt M, Alabi S, Cowen MH, Brito-Vargas P, Hoffman-Kim D, Gamsiz Uzun ED, Schlessinger A, Jones RN, Morrow EM. Human neurons from Christianson syndrome iPSCs reveal mutation-specific responses to rescue strategies. Sci Transl Med. 2021 Feb 10;13(580):eaaw0682. doi: 10.1126/scitranslmed.aaw0682.
82. Smith RHB, Khan ZM, Ung PM, Scopton AP, Silber L, Mack SM, Real AM, Schlessinger A*, Dar AC*. Type II Binders Targeting the “GLR-Out” Conformation of the Pseudokinase STRADα. Biochemistry. 2021 Feb 2;60(4):289-302. doi: 10.1021/acs.biochem.0c00714.
81. Bosshart PD, Charles RP, Garibsingh RA, Schlessinger A, Fotiadis D. SLC16 Family: From Atomic Structure to Human Disease. Trends Biochem Sci. 2021 Jan;46(1):28-40. doi: 10.1016/j.tibs.2020.07.005.
80. van Hasselt JGC, Rahman R, Hansen J, Stern A, Shim JV, Xiong Y, Pickard A, Jayaraman G, Hu B, Mahajan M, Gallo JM, Goldfarb J, Sobie EA, Birtwistle MR, Schlessinger A*, Azeloglu EU*, Iyengar R.* Transcriptomic profiling of human cardiac cells predicts protein kinase inhibitor-associated cardiotoxicity. Nat Commun. 2020 Sep 23;11(1):4809. doi: 10.1038/s41467-020-18396-7.
79. Zhao Y, Ung PMU, Zahoranszky-Kohalmi G, Zakharov AV, Martinez NJ, Simeonov A, Glaaser IW, Rai G, Schlessinger A, Marugan JJ, Slesinger PA. Identification of a G-Protein-Independent Activator of GIRK Channels. Cell Rep. 2020 Jun 16;31(11):107770. doi: 10.1016/j.celrep.2020.107770.
78. Ndaru E, Garibsingh RA, Zielewicz L, Schlessinger A, Grewer C. Interaction of the neutral amino acid transporter ASCT2 with basic amino acids. Biochem J. 2020 Apr 30;477(8):1443-1457.
77. Rahman R, Kodesh A, Levine SZ, Sandin S, Reichenberg A*, Schlessinger A*. Identification of newborns at risk for autism using electronic medical records and machine learning. Eur Psychiatry 26;63(1):e22. doi: 10.1192/j.eurpsy.2020.17.
76. Khamrui S, Ung PMU, Secor C, Schessinger A, Lazarus MB. (2020) High Resolution Structure and Inhibition of the Schizophrenia-Linked Pseudokinase ULK4. J Am Chem Soc 142(1):33-37.
75. Garibsingh RA, Schlessinger A. Advances and Challenges in Rational Drug Design for SLCs. Trends Pharmacol Sci. 40(10):790-800.
74. Hall C, Wolfe H, Wells A, Chien HC, Colas C, Schlessinger A, Giacomini KM, Thomas AA. l-Type amino acid transporter 1 activity of 1,2,3-triazolyl analogs of l-histidine and l-tryptophan. Bioorg Med Chem Lett. 29(16):2254-2258.
73. Ung PMU, DeVita RJ, Schlessinger A (2019) Encounter and react: computer-guided design of covalent inhibitors. Cell Chem Biol 26 (1):6-8.
72. Kuzina ES, Ung PMU, Mohanty J, Tome F, Choi J, Pardon E, Steyaert J, Lax I, Schlessinger A, Schlessinger J, Lee S (2019) Structures of ligand occupied β-klotho complexes reveal molecular mechanism underlying endocrine FGF specificity and activity. Proc Natl Acad Sci U S A 116 (16):7819-7824.
71. Ung PMU*, Sonoshita M*, Scopton AP, Dar AC, Cagan RL, Schlessinger A (2019) Integrated computational and Drosophila cancer model platform captures previously unappreciated chemicals perturbing a kinase network. PLoS Comput Biol 15 (4): e1006878.
70. Enogieru OJ, Ung PMU, Yee SW, Schlessinger A, Giacomini KM (2019) Functional and Structural Analysis of Rare SLC2A2 Mutations Associated with Fanconi-Bickel Syndrome and Metabolic Traits. Human Mol Genet 40 (7):983-995.
69. Ndaru E, Garibsingh RA, Shi Y, Wallace E, Zakrepine P, Schlessinger A, Grewer C (2019) Novel alanine serine cysteine transporter 2 (ASCT2) inhibitors based on sulfonamide and sulfonic acid ester scaffolds. J Gen Physiol 151 (3):357.
68. Liu PH, Shah R, Li Y, Arora A, Ung PMU, Raman R, Gorbatenko A, Kozono S, Zhou XZ, Brechin V, Barbaro JM, Thompson R, White RM, Aguirre-Ghiso JA, Heymach JV, Lu KP, Silva JM, Panageas KS, Schlessinger A, Maki RG, Skinner HD, de Stanchina E, Sidi S (2019) An IRAK1-PIN1 Signalling Axis Drives Intrinsic Tumor Resistance to Radiation Therapy. Nature Cell Biol 21:203-213.
67. Dewulf JP, Wiame E, Dorboz I, Elmaleh-Bergès M, Imbard A, Dumitriu D, Rak M, Bourillon A, Helaers R, Malla A, Renaldo F, Boespflug-Tanguy O, Vincent MF, Benoist JF, Wevers RA, Schlessinger A, Van Schaftingen E, Nassogne MC, Schiff M. SLC13A3 variants cause acute reversible leukoencephalopathy and αKG accumulation (2019). Ann Neurol 85 (3):385-395.
66. Rahman R*, Ung PMU*, Schlessinger A (2019) KinaMetrix: A Web Resource to Investigate Kinase Conformations and Inhibitor Space. Nucleic Acids Res 47 (D1):D361-D366.
65. Janecka M, Kodesh A, Levine SZ, Lusskin SI, Viktorin A, Rahman R, Buxbaum JD, Schlessinger A, Sandin S, Reichenberg A (2018) Association of Autism Spectrum Disorder With Prenatal Exposure to Medication Affecting Neurotransmitter Systems. JAMA Psychiatry 75 (12):1217-1224.
64. Kumar K*, Ung PMU*, Wang P, Li H, Andrews MK, Sewart AF, Schlessinger A^, DeVita RJ^ (2018) Novel Selective Thiadiazine DYRK1A Inhibitor Lead Scaffold with Human Pancreatic Beta-Cell Proliferation Activity. Euro J Med Chem 157:1005-1016.
63. Chien HC*, Colas C*, Fink C*, Springer S*, Stoner L*, Zur, AA, Venteicher B, Campbell J, Hall C, Flint A, Augustyn E, Hernandez C, Heeren N, Hansen L, Anthony A, Bauer J, Fotiadis D, Schlessinger A^, Giacomini KM^, Thomas AA^ (2018) Reevaluating the Substrate Specificity of the L-Type Amino Acid Transporter (LAT1). J Med Chem 61(16):7358-7373.
62. Schlessinger A, Welch MA, van Vlijjmen H, Korzekwa K, Swaan PW, Matsson P (2018) Molecular Modeling of Drug–Transporter Interactions—an International Transporter Consortium Perspective. Clin Pharmacol Ther104 (5):818-835.
61. Garibsingh RA, Otte NJ, Ndaru E, Colas C, Grewer C, Holst J, Schlessinger A (2018) Homology modeling informs ligand discovery for the glutamine transporter ASCT2. Front Chem 6:279.
60. Ung PMU*, Rahman R*, Schlessinger A (2018) Redefining the protein kinase conformational space with machine learning. Cell Chem Biol 25 (7):916-924. e2.
59. Ilgü H, Jeckelmann JM, Colas C, Ucurum Z, Schlessinger A, Fotiadis D (2018) Effects of Mutations and Ligands on the Thermostability of the l-Arginine/Agmatine Antiporter AdiC and Deduced Insights into Ligand-Binding of Human l-Type Amino Acid Transporters. Int J Mol Sci 19 (3). pii: E918.
58. Sonoshita M, Scopton AP, Ung PMU, Murray MA, Silber L, Maldonado AY, Real A, Schlessinger A, Cagan RL, Dar AC (2018) A whole-animal platform to advance a clinical kinase inhibitor into new disease space. Nat Chem Biol 14 (3):291-298.
57. Schlessinger A, Abagyan R, Carlson HA, Dang KK, Guinney J, Cagan RL (2017) Multi-targeting Drug Community Challenge. Cell Chem Biol 24 (12):1434-1435.
56. Colas C, Masuda M, Sugio K, Miyauchi S, Hu Y, Smith DE, Schlessinger A (2017) Chemical Modulation of the Human Oligopeptide Transporter 1, hPepT1. Mol Pharm 14 (12):4685-4693.
55. Heimann AS, Gupta A, Gomes I, Rayees R, Schlessinger A, Ferrod4d4d4ES, Unterwald EM, Devi LA (2017) Generation of G protein-coupled receptor antibodies differentially sensitive to conformational states. PLoS One 12 (11):e0187306.
54. Colas C, Schlessinger A^, Pajor AM^ (2017) Mapping Functionally Important Residues in the Na+/Dicarboxylate Cotransporter, NaDC1. Biochemistry 56 (33):4432-4441.
53. Stecula A, Schlessinger A, Giacomini KM, Sali A (2017) Human Concentrative Nucleoside Transporter 3 (hCNT3, SLC28A3) Forms a Cyclic Homotrimer. Biochemistry 56 (27):3475-3483.
52. Singh K, Tanui R, Gameiro A, Eisenberg G, Colas C, Schlessinger A, Grewer C (2016) Structure activity relationships of benzylproline-derived inhibitors of the glutamine transporter ASCT2 (2017) Bioorg Med Chem Lett 27 (3):398-402.
51. Tărlungeanu DC, Deliu E, Dotter CP, Kara M, Janiesch PC, Scalise M, Galluccio M, Tesulov M, Morelli E, Sonmez FM, Bilguvar K, Ohgaki R, Kanai Y, Johansen A, Esharif S, Ben-Omran T, Topcu M, Schlessinger A, Indiveri C, Duncan KE, Caglayan AO, Gunel M, Gleeson JG, Novarino G (2016) Impaired Amino Acid Transport at the Blood Brain Barrier Is a Cause of Autism Spectrum Disorder. Cell 167 (6):1481-1494.e18.
50. Colas C & Schlessinger A^ (2016) Ligand discovery for the nutrient transporters ASCT2 and LAT-1 from homology modeling and virtual screening. Ed: G Ecker and H Sitte.
49. Gundersen GW, Jagodnik KM, Woodland H, Fernandez NF, Sani K, Dohlman AB, Ung PMU, Monteiro CD, Schlessinger A, Ma’ayan A (2016) GEN3VA: aggregation and analysis of gene expression signatures from related studies BMC Bioinf 17:461.
48. Zur AA , Chien H-C, Augustyn E, Flint A, Heeren N, Finke K, Hernandez C, Hansen L, Miller S, Lin L, Giacomini KM, Colas C, Schlessinger A, Thomas AA (2016) LAT1 activity of carboxylic acid bioisosteres: Evaluation of hydroxamic acids as substrates Bioorg Med Chem Lett 26 (20):5000-5006.
47. Klotz J, Porter BE, Colas C, Schlessinger A, Pajor AM (2016) Mutations in the Na+/citrate cotransporter NaCT (SLC13A5) in pediatric patients with epilepsy and developmental delay Mol Med 22:310-221.
46. Birtwistle MR, Hansen J, Gallo JM, Muppirisetty S, Ung PMU, Iyengar R, Schlessinger A (2016) Systems Pharmacology: An Overview. American Association of Pharmaceutical Scientists. Systems Pharmacology and Pharmacodynamics. 53-80. Publisher: Springer, Cham.
45. Truong TH, Ung PMU, Palde PB, Paulsen CE, Schlessinger A, Carroll KS (2016) Molecular Basis for Redox Activation of Epidermal Growth Factor Receptor Kinase Cell Chem Biol 23 (7):837-848.
44. Colas C, Ung PMU, Schlessinger A^ (2016) SLC Transporters: Structure, Function, and Drug Discovery. MedChemComm 7 (6):1069-1081.
43. Colas C, Smith DE, Schlessinger A^ (2016) Computing substrate selectivity in a peptide transporter. Cell Chem Biol 23 (2): 211-213. Commentary
42. Ung PMU, Song W, Cheng L, Zhao X, Hu H, Chen L, Schlessinger A (2016) Inhibitor Discovery for the Human GLUT1 from Homology Modeling and Virtual Screening ACS Chem Biol 11 (7):1908-16
41. Augustyn E, Finke K, Zur AA, Hansen L, Heeren N, Chien HC, Lin L, Giacomini KM, Colas C, Schlessinger A, Thomas AA (2016) LAT-1 activity of meta-substituted phenylalanine and tyrosine analogs Bioorg Med Chem Lett 26 (11):2616-2621.
40. Salvo E, Alabi S, Liu B, Schlessinger A, Bechhofer DH (2016) Interaction of Bacillus subtilis Polynucleotide Phosphorylase and RNase Y: Structural Mapping and Effect on mRNA Turnover. J Biol Chem 291 (13):6655-6663.
39. Colas C, Grewer C, Otte NJ, Gameiro A, Albers T, Singh K, Shere H, Bonomi M, Holst J, and Schlessinger A (2015) Ligand discovery for the Alanine-Serine-Cysteine transporter (ASCT2, SLC1A5) from homology modeling and virtual screening. PLoS Comput Biol 11 (10):e1004477.
38. Vicedo E, Schlessinger A, Rost B (2015) Environmental Pressure May Change the Composition Protein Disorder in Prokaryotes. PLoS One 10 (8):e0133990.
37. Colas C, Pajor AM, Schlessinger A (2015) Structure-Based Identification of Inhibitors for the SLC13 Family of Na(+)/Dicarboxylate Cotransporters. Biochemistry 54 (31):4900-4908.
36. Ung PMU, Schlessinger A (2015) DFGmodel: Predicting protein kinase structures in inactive states for structure-based discovery of type-II inhibitors. ACS Chem Biol 10 (1):269-278.
35. Kuechler A, Zink AM, Wieland T, Lüdecke HJ, Cremer K, Salviati L, Magini P, Najafi K, Zweier C, Czeschik JC, Aretz S, Endele S, Tamburrino F, Pinato C, Clementi M, Gundlach J, Maylahn C, Mazzanti L, Wohlleber E, Schwarzmayr T, Kariminejad R, Schlessinger A, Wieczorek D, Strom TM, Novarino G, Engels H (2015) Loss-of-function variants of SETD5 cause intellectual disability and the core phenotype of microdeletion 3p25.3 syndrome.
Eur J Hum Genet 23 (6):753-760.
34. Schlessinger A, Sun NN, Colas C, Pajor AM (2014) Determinants of substrate and cation transport in the human Na+/dicarboxylate cotransporter, NaDC3. J Biol Chem 289 (24):16998-17008.
33. Schlessinger A. (2014) Characterizing the structure, function, and evolution of human Solute Carrier (SLC) transporters using computational approaches. In: Membrane Transport Mechanism: 3D Structure and Beyond (Springer Series in Biophysics). Ed: R. Krämer and C Ziegler, pp. 23-58, Springer, ISBN-13: 978-36425383.
32. Yachdav G, Kloppmann E, Kajan L, Hecht M, Goldberg T, Hamp T, Schafferhans A, Roos M, Bernhofer M, Richter L, Ashkenazy H, Punta M, Schlessinger A, Bromberg Y, Schneider R, Vriend G, Sander C, Ben-Tal N, Rost B (2014) PredictProtein – open online prediction of protein structure and function. Nucleic Acids Res 42 (Web Server issue):W337-W343.
31. Feiglin A, Ashkenazi S, Schlessinger A, Rost B, Ofran Y (2014) Co-expression and co-localization of hub proteins and their partners are encoded in protein sequence. Mol Biosyst 210 (4):787-794.
30. Waight AB, Pedersen BP, Schlessinger A, Bonomi M, Chau BH, Roe-Zurz Z, Risenmay AJ, Sali A, Stroud RM (2013) Structural basis for alternating access of a eukaryotic calcium/proton exchanger. Nature 496 (7446):533-536.
29. Schlessinger A^, Yee SW, Sali A, Giacomini KM (2013) SLC classification: an update. Clin Pharmacol Ther 94 (1):19-23.
28. Schlessinger A, Khuri N, Giacomini KM, Sali A (2013) Molecular modeling and ligand docking for Solute Carrier (SLC) transporters. Curr Top Med Chem 13 (7):843-856.
27. van Dam TJ, Townsend MJ, Turk M, Schlessinger A, Sali A, Field MC, Huynen MA (2013) Evolution of modular intraflagellar transport from a coatomer-like progenitor. Proc Natl Acad Sci U S A 110 (17):6943-6948.
26. Pedersen BP, Kumar H, Waight AB, Risenmay AJ, Roe-Zurz Z, Chau BH, Schlessinger A, Bonomi M, Harries W, Sali A, Johri AK, Stroud RM (2013) Crystal structure of a eukaryotic phosphate transporter. Nature 496 (7446):533-536.
25. Geier EG*, Schlessinger A*, Fan H, Gable JE, Irwin JJ, Sali A, Giacomini KM (2013) Structure-based ligand discovery for the Large-neutral Amino Acid Transporter 1, LAT-1. Proc Natl Acad Sci U S A 110 (14):5480-5485.
24. Pieper U, Schlessinger A, Kloppmann E, Chang GA, Chou JJ, Dumont ME, Fox BG, Fromme P, Hendrickson WA, Malkowski MG, Rees DC, Stokes DL, Stowell MH, Wiener MC, Rost B, Stroud RM, Stevens RC, Sali A (2013) Coordinating the impact of structural genomics on the human alpha-helical transmembrane proteome. Nat Struct Mol Biol 20 (2):135-138.
23. Schlessinger A*, Wittwer MB*, Dahlin A, Khuri N, Bonomi M, Fan H, Giacomini KM, Sali A (2012) High Selectivity of the gamma-Aminobutyric Acid Transporter 2 (GAT-2, SLC6A13) Revealed by Structure-based Approach. J Biol Chem 287 (45):37745-37756.
22. Choi JH, Yee SW, Ramirez AH, Morrissey KM, Jang GH, Joski PJ, Mefford JA, Hesselson SE, Schlessinger A, Jenkins G, Castro RA, Johns SJ, Stryke D, Sali A, Ferrin TE, Witte JS, Kwok PY, Roden DM, Wilke RA, McCarty CA, Davis RL, Giacomini KM (2011) A common 5′-UTR variant in MATE2-K is associated with poor response to metformin. Clin Pharmacol Ther 90 (5):674-684.
21. Carlsson J, Coleman RG, Setola V, Irwin JJ, Fan H, Schlessinger A, Sali A, Roth BL, Shoichet BK (2011) Ligand discovery from a dopamine D3 receptor homology model and crystal structure. Nat Chem Biol 7 (11):769-778.
20. Schlessinger A, Geier E, Fan H, Irwin JJ, Shoichet BK, Giacomini KM, Sali A (2011) Structure-based discovery of prescription drugs that interact with the norepinephrine transporter, NET. Proc Natl Acad Sci U S A 108 (38):15810-15815.
19. Schlessinger A, Schaefer C, Vicedo E, Schmidberger M, Punta M, Rost B (2011) Protein disorder–a breakthrough invention of evolution? Curr Opin Struct Biol 21 (3):412-418.
18. Dokudovskaya S, Waharte F, Schlessinger A, Pieper U, Devos DP, Cristea IM, Williams R, Salamero J, Chait BT, Sali A, Field MC, Rout MP, Dargemont C (2011) A conserved coatomer-related complex containing Sec13 and Seh1 dynamically associates with the vacuole in Saccharomyces cerevisiae. Mol Cell Proteomics 10 (6):M110 006478.
17. Pieper U, Webb BM, Barkan DT, Schneidman-Duhovny D, Schlessinger A, Braberg H, Yang Z, Meng EC, Pettersen EF, Huang CC, Datta RS, Sampathkumar P, Madhusudhan MS, Sjolander K, Ferrin TE, Burley SK, Sali A (2011) ModBase, a database of annotated comparative protein structure models, and associated resources. Nucleic Acids Res 39 (Database issue):D465-474.
16. Chen L, Takizawa M, Chen E, Schlessinger A, Segenthelar J, Choi JH, Sali A, Kubo M, Nakamura S, Iwamoto Y, Iwasaki N, Giacomini KM (2010) Genetic polymorphisms in organic cation transporter 1 (OCT1) in Chinese and Japanese populations exhibit altered function. J Pharmacol Exp Ther 335 (1):42-50.
15. Chen L, Pawlikowski B, Schlessinger A, More SS, Stryke D, Johns SJ, Portman MA, Chen E, Ferrin TE, Sali A, Giacomini KM (2010) Role of organic cation transporter 3 (SLC22A3) and its missense variants in the pharmacologic action of metformin. Pharmacogenet Genomics 20 (11):687-699.
14. Lasker K, Phillips JL, Russel D, Velázquez-Muriel J, Schneidman-Duhovny D, Tjioe E, Webb B, Schlessinger A, Sali A (2010) Integrative structure modeling of macromolecular assemblies from proteomics data. Mol Cell Proteomics 9 (8):1689-702.
13. Gruswitz F, Chaudhary S, Ho JD, Schlessinger A, Pezeshki B, Ho CM, Sali A, Westhoff CM, Stroud RM (2010) Function of human Rh based on structure of RhCG at 2.1 A. Proc Natl Acad Sci U S A 107 (21):9638-9643.
12. Schaefer C, Schlessinger A, Rost B (2010) Protein secondary structure appears to be robust under in silico evolution while protein disorder appears not to be. Bioinformatics 26 (5):625-631.
11. Schlessinger A, Matsson P, Shima JE, Pieper U, Yee SW, Kelly L, Apeltsin L, Stroud RM, Ferrin TE, Giacomini KM, Sali A (2010) Comparison of human solute carriers. Protein Sci 19 (3):412-428.
10. Schlessinger A, Punta M, Yachdav G, Kajan L, Rost B (2009) Improved disorder prediction by combination of orthogonal approaches. PLoS One 4 (2):e4433.
9. Galea CA, High AA, Obenauer JC, Mishra A, Park CG, Punta M, Schlessinger A, Ma J, Rost B, Slaughter CA, Kriwacki RW (2009) Large-scale analysis of thermostable, mammalian proteins provides insights into the intrinsically disordered proteome. J Proteome Res 8 (1):211-226.
8. Ofran Y*, Schlessinger A*, Rost B (2008) Automated identification of complementarity determining regions (CDRs) reveals peculiar characteristics of CDRs and B cell epitopes. J Immunol 181 (9):6230-6235.
7. Schlessinger A, Punta M, Rost B (2007) Natively unstructured regions in proteins identified from contact predictions. Bioinformatics 23 (18):2376-2384.
6. Schlessinger A, Liu J, Rost B (2007) Natively unstructured loops differ from other loops. PLoS Comput Biol 3 (7):e140.
5. Greenbaum JA, Andersen PH, Blythe M, Bui HH, Cachau RE, Crowe J, Davies M, Kolaskar AS, Lund O, Morrison S, Mumey B, Ofran Y, Pellequer JL, Pinilla C, Ponomarenko JV, Raghava GP, van Regenmortel MH, Roggen EL, Sette A, Schlessinger A, Sollner J, Zand M, Peters B (2007) Towards a consensus on datasets and evaluation metrics for developing B-cell epitope prediction tools. J Mol Recognit 20 (2):75-82.
4. Schlessinger A, Yachdav G, Rost B (2006) PROFbval: predict flexible and rigid residues in proteins. Bioinformatics 22 (7):891-893.
3. Schlessinger A*, Ofran Y*, Yachdav G, Rost B (2006) Epitome: database of structure-inferred antigenic epitopes. Nucleic Acids Res 34 (Database issue):D777-780.
2. Schlessinger A, Rost B (2005) Protein flexibility and rigidity predicted from sequence. Proteins 61 (1):115-126.
1. Petrey D, Xiang Z, Tang CL, Xie L, Gimpelev M, Mitros T, Soto CS, Goldsmith-Fischman S, Kernytsky A, Schlessinger A, Koh IY, Alexov E, Honig B (2003) Using multiple structure alignments, fast model building, and energetic analysis in fold recognition and homology modeling. Proteins 53 Suppl 6:430-435.